T. A. Yap, J. G. Aerts, S. Popat, and D. A. Fennell, Novel insights into mesothelioma biology and implications for therapy, Nat. Rev. Cancer, vol.17, pp.475-488, 2017.

D. Jean, J. Daubriac, F. Le-pimpec-barthes, F. Galateau-salle, and M. C. Jaurand, Molecular changes in mesothelioma with an impact on prognosis and treatment, Arch. Pathol. Lab. Med, vol.136, pp.277-293, 2012.

R. Bueno, Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations, Nat. Genet, vol.48, pp.407-416, 2016.

P. G. Betta, C. Magnani, T. Bensi, N. F. Trincheri, and S. Orecchia, Immunohistochemistry and molecular diagnostics of pleural malignant mesothelioma, Arch. Pathol. Lab. Med, vol.136, pp.253-261, 2012.
DOI : 10.5858/arpa.2010-0604-ra

S. X. Huang, M. C. Jaurand, D. W. Kamp, J. Whysner, and T. K. Hei, Role of mutagenicity in asbestos fiber-induced carcinogenicity and other diseases, J. Toxicol. Environ. Health B Crit. Rev, vol.14, pp.179-245, 2011.

A. De-reynies, Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition, Clin. Cancer Res, vol.20, pp.1323-1334, 2014.

R. Tranchant, Co-occurring mutations of tumor suppressor genes, LATS2 and NF2, in malignant pleural mesothelioma, Clin. Cancer Res, vol.23, pp.3191-3202, 2017.

J. Hmeljak, Integrative molecular characterization of malignant pleural mesothelioma, Cancer Discov, vol.8, pp.1548-1565, 2018.

F. Lopez-rios, Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction, Cancer Res, vol.66, pp.2970-2979, 2006.

G. J. Gordon, Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling, Am. J. Pathol, vol.166, pp.1827-1840, 2005.

T. Broad-institute and . Center, Analysis-ready standardized TCGA data from Broad GDAC Firehose stddata__2015_06_01 run. Broad Institute of MIT and Harvard, 2015.

J. M. Garcia-heredia and A. Carnero, The cargo protein MAP17 (PDZK1IP1) regulates the immune microenvironment, Oncotarget, vol.8, pp.98580-98597, 2017.

Y. Shen, X. Chen, J. He, D. Liao, and X. Zu, Axl inhibitors as novel cancer therapeutic agents, Life Sci, vol.198, pp.99-111, 2018.
DOI : 10.1016/j.lfs.2018.02.033

T. Etoh, Increased DNA methyltransferase 1 (DNMT1) protein expression correlates significantly with poorer tumor differentiation and frequent DNA hypermethylation of multiple CpG islands in gastric cancers, Am. J. Pathol, vol.164, pp.689-699, 2004.

M. E. Figueroa, Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation, Cancer Cell, vol.18, pp.553-567, 2010.

B. C. Christensen, Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome, Cancer Res, vol.69, pp.227-234, 2009.
DOI : 10.1158/0008-5472.can-08-2586
URL : http://cancerres.aacrjournals.org/content/69/1/227.full.pdf

K. C. Mcloughlin, A. S. Kaufman, and D. S. Schrump, Targeting the epigenome in malignant pleural mesothelioma, Transl. Lung Cancer Res, vol.6, pp.350-365, 2017.

L. Nicole, R. Cappellesso, T. Sanavia, V. Guzzardo, and A. Fassina, MiR-21 over-expression and programmed cell death 4 down-regulation features malignant pleural mesothelioma, Oncotarget, vol.9, pp.17300-17308, 2018.

S. R. Pfeffer, C. H. Yang, and L. M. Pfeffer, The role of miR-21 in cancer, Drug. Dev. Res, vol.76, pp.270-277, 2015.

J. Li, Y. Song, Y. Wang, J. Luo, and W. Yu, MicroRNA-148a suppresses epithelial-to-mesenchymal transition by targeting ROCK1 in non-small cell lung cancer cells, Mol. Cell. Biochem, vol.380, pp.277-282, 2013.

H. I. Pass, hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma, Cancer Res, vol.70, pp.1916-1924, 2010.

Y. Liu, miR-10a suppresses colorectal cancer metastasis by modulating the epithelial-to-mesenchymal transition and anoikis, Cell Death Dis, vol.8, p.2739, 2017.
DOI : 10.1038/cddis.2017.61
URL : https://www.nature.com/articles/cddis201761.pdf

S. Inoguchi, Tumour-suppressive microRNA-24-1 inhibits cancer cell proliferation through targeting FOXM1 in bladder cancer, FEBS Lett, vol.588, pp.3170-3179, 2014.
DOI : 10.1016/j.juro.2014.02.846

Q. Huang, The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis, Nat. Cell Biol, vol.10, pp.202-210, 2008.
DOI : 10.1038/ncb1681

W. Yang, Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells, Nucleic Acids Res, vol.41, pp.955-961, 2013.

W. Blum, Stem cell factor-based identification and functional properties of in vitro-selected subpopulations of malignant mesothelioma cells, Stem Cell Rep, vol.8, pp.1005-1017, 2017.

A. Scherpereel, F. Wallyn, S. M. Albelda, and C. Munck, Novel therapies for malignant pleural mesothelioma, Lancet Oncol, vol.19, pp.161-172, 2018.
DOI : 10.1016/s1470-2045(18)30100-1

E. Becht, Immune and stromal classification of colorectal cancer is associated with molecular subtypes and relevant for precision immunotherapy, Clin. Cancer Res, vol.22, pp.4057-4066, 2016.

L. Zhai, IDO1 in cancer: a Gemini of immune checkpoints, Cell. Mol. Immunol, vol.15, pp.447-457, 2018.

J. L. Lines, L. F. Sempere, T. Broughton, L. Wang, and R. Noelle, VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy, Cancer Immunol. Res, vol.2, pp.510-517, 2014.
DOI : 10.1158/2326-6066.cir-14-0072
URL : http://cancerimmunolres.aacrjournals.org/content/canimm/2/6/510.full.pdf

D. B. Oien, T. Garay, S. Eckstein, and J. Chien, Cisplatin and pemetrexed activate AXL and AXL inhibitor BGB324 enhances mesothelioma cell death from chemotherapy, Front. Pharmacol, vol.8, p.970, 2017.
DOI : 10.3389/fphar.2017.00970
URL : https://www.frontiersin.org/articles/10.3389/fphar.2017.00970/pdf

S. E. Herrick and S. E. Mutsaers, Mesothelial progenitor cells and their potential in tissue engineering, Int. J. Biochem. Cell. Biol, vol.36, pp.621-642, 2004.
DOI : 10.1016/j.biocel.2003.11.002

V. Gkretsi and T. Stylianopoulos, Cell adhesion and matrix stiffness: coordinating cancer cell invasion and metastasis, Front. Oncol, vol.8, p.145, 2018.
DOI : 10.3389/fonc.2018.00145
URL : https://www.frontiersin.org/articles/10.3389/fonc.2018.00145/pdf

W. Q. Zhang, Targeting YAP in malignant pleural mesothelioma, J. Cell. Mol. Med, vol.21, pp.2663-2676, 2017.

L. Wei, M. Surma, S. Shi, N. Lambert-cheatham, and J. Shi, Novel insights into the roles of Rho kinase in cancer, Arch. Immunol. Ther. Exp, vol.64, pp.259-278, 2016.

J. M. Kreahling, MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells, Mol. Cancer Ther, vol.11, pp.174-182, 2012.
DOI : 10.1158/1535-7163.mct-11-0529
URL : http://mct.aacrjournals.org/content/11/1/174.full.pdf

C. J. Matheson, D. S. Backos, and P. Reigan, Targeting WEE1 kinase in cancer, Trends Pharmacol. Sci, vol.37, pp.872-881, 2016.

J. Minnema-luiting, H. Vroman, J. Aerts, and R. Cornelissen, Heterogeneity in immune cell content in malignant pleural mesothelioma, Int. J. Mol. Sci, vol.19, p.1041, 2018.

R. Hassan, Mesothelin immunotherapy for cancer: ready for prime time?, J. Clin. Oncol, vol.34, pp.4171-4179, 2016.

V. Janelle and A. Lamarre, Role of the complement system in NK cell-mediated antitumor T-cell responses, Oncoimmunology, vol.3, p.27897, 2014.

A. Scherpereel, Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial, Lancet Oncol, vol.20, pp.239-253, 2019.

S. Rondeau, ATM has a major role in the double-strand break repair pathway dysregulation in sporadic breast carcinomas and is an independent prognostic marker at both mRNA and protein levels, Br. J. Cancer, vol.112, pp.1059-1066, 2015.

N. Zhang, Predicting tumor purity from methylation microarray data, Bioinformatics, vol.31, pp.3401-3405, 2015.
DOI : 10.1093/bioinformatics/btv370
URL : https://academic.oup.com/bioinformatics/article-pdf/31/21/3401/17122211/btv370.pdf

Y. Qin, H. Feng, M. Chen, H. Wu, and X. Zheng, InfiniumPurify: an R package for estimating and accounting for tumor purity in cancer methylation research, Genes Dis, vol.5, pp.43-45, 2018.

M. Toyota, CpG island methylator phenotype in colorectal cancer, Proc. Natl Acad. Sci. USA, vol.96, pp.8681-8686, 1999.

F. Vigneault, High-throughput multiplex sequencing of miRNA, Curr. Protoc. Hum. Genet, vol.73, 2012.
DOI : 10.1002/0471142905.hg1112s73
URL : http://europepmc.org/articles/pmc3673877?pdf=render

G. Barturen, sRNAbench: profiling of small RNAs and its sequence variants in single or multi-species high-throughput experiments, Methods, vol.1, pp.21-31, 2014.

J. H. Bullard, E. Purdom, K. D. Hansen, and S. Dudoit, Evaluation of statistical methods for normalization and differential expression in mRNA-Seq experiments, BMC Bioinform, vol.11, p.94, 2010.

C. H. Chou, miRTarBase 2016: updates to the experimentally validated miRNA-target interactions database, Nucleic Acids Res, vol.44, pp.239-247, 2016.

I. S. Vlachos, DIANA-TarBase v7.0: indexing more than half a million experimentally supported miRNA:mRNA interactions, Nucleic Acids Res, vol.43, pp.153-159, 2015.

E. Cerami, The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data, Cancer Discov, vol.2, pp.401-404, 2012.
DOI : 10.1158/2159-8290.cd-12-0095
URL : http://cancerdiscovery.aacrjournals.org/content/2/5/401.full.pdf

J. Gao, Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal, Sci. Signal, vol.6, p.1, 2013.

L. Marisa, Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value, PLoS Med, vol.10, p.1001453, 2013.

J. Guinney, The consensus molecular subtypes of colorectal cancer, Nat. Med, vol.21, pp.1350-1356, 2015.

M. V. Kuleshov, Enrichr: a comprehensive gene set enrichment analysis web server 2016 update, Nucleic Acids Res, vol.44, pp.90-97, 2016.

M. D. Wilkerson and D. N. Hayes, ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking, Bioinformatics, vol.26, pp.1572-1573, 2010.

L. Zeng, In vitro effects of recombinant human interferon gamma on human mesothelioma cell lines, Int. J. Cancer, vol.55, pp.515-520, 1993.

M. Ilie, Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms, PLoS One, vol.12, p.183023, 2017.

, 2014-2019) and the Société Française de Chirurgie-Thoracique et Cardiovasculaire (SFCTV). LQ was supported by grants from Cancéropôle Région Île

, Coup d'Elan de la Fondation Bettencourt-Shueller, the SIRIC CAR-PEM, the Institut thématique multi-organismes (ITMO) Cancer (Plan Cancer 2014-2019) and Cancéropôle Île-de-France. The Institut Curie RPPA platform is supported by Cancéropôle Ile-de-France and we thank Bérengère Ouine et Aurélie Cartier for acquisition of RPPA data. English was improved by, The Inserm research unit is supported by the Labex OncoImmunology (investissement d'avenir)